In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.
Urinary activity, reportedly a common feature of prostate-specific membrane antigen positron emission tomography (PSMA PET) radiopharmaceuticals, can have an adverse impact on imaging interpretation for detection of new or recurrent prostate cancer.
At initial staging, intense urinary activity with PET radiopharmaceuticals can obscure surrounding areas of the bladder, including the prostate, primary prostate lesions below the bladder, small lymph nodes around the bladder and invasion of the primary prostate tumor into surrounding structures such as the seminal vesicles, noted Phillip Kuo, M.D., Ph.D., F.A.C.R., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Dr. Kuo also pointed out that high urinary activity can make it more challenging to diagnose recurrence at the vesicourethral anastomosis, the most common site for prostate cancer recurrence.
(Editor’s note: For related content, see “PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer” and “Can an Emerging PSMA/PET Agent Improve Detection of Prostate Cancer Recurrence in Patients with Low PSAs?”)
However, in a recent study looking at phase 3 from the SPOTLIGHT and LIGHTHOUSE trials, Dr. Kuo and colleagues examined the use of the injectable PET imaging agent flotufolastat F 18 (POSLUMA®, Blue Earth Diagnostics) in 712 patients with either newly diagnosed or recurrent prostate cancer. The study findings, presented at the SNMMI conference, demonstrated that for 96 percent of the cohort, it was possible to distinguish between urinary activity and disease uptake.
“In the vast majority of the cases, urinary activity (with flotufolastat F 18) is low enough in the ureters and bladder that we think it will not potentially affect your ability to detect disease in the pelvis,” noted Dr. Kuo, a professor of medical imaging, biomedical engineering, and medicine at the University of Arizona College of Medicine.
For more insights from Dr. Kuo, watch the video below.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.